Penn-BioNTech Fund Backs Emvena Therapeutics
The PxB Fund, a $50 million venture fund, made its first investment in Emvena, a startup developing placenta-targeted mRNA medicines for preeclampsia.
Updated on Nov. 4, 2026 in Biotech
Live Poll
Should the government put more funding into medical research on neglected conditions?
The Penn-BioNTech Innovative Therapeutics Seed Fund has invested in Emvena Therapeutics, a company developing placenta-targeted mRNA medicines for preeclampsia. Emvena is the first company launched and financed by the PxB Fund, a $50 million venture capital fund formed by the University of Pennsylvania, BioNTech SE, and Osage University Partners.
Why it matters
Preeclampsia affects an estimated 2%-8% of pregnancies worldwide, and no approved therapy addresses the underlying disease. The investment moves technology developed in a University of Pennsylvania laboratory toward clinical development.
The lipid nanoparticle platform preferentially delivers mRNA to the placenta, as shown in Mitchell Lab research, and VEGF mRNA delivery reduced disease severity in mouse models of preeclampsia. The investment amount and timeline to human trials were not disclosed.
The players
Emvena Therapeutics
A startup developing placenta-targeted mRNA medicines for preeclampsia, founded in 2026 and advancing technology from the University of Pennsylvania.
PxB Fund
A $50 million venture capital fund formed by the University of Pennsylvania, BioNTech SE, and Osage University Partners to back startups from Penn research.
Osage University Partners
A venture firm with roughly $800 million under management that has invested in more than 150 startups, including more than 10 from Penn.
Michael J. Mitchell
A University of Pennsylvania researcher whose laboratory developed the lipid nanoparticle technology underlying Emvena's medicines.
The details
Emvena is advancing technology from the laboratory of Michael J. Mitchell at the University of Pennsylvania, using a lipid nanoparticle platform to deliver mRNA to the placenta. Seed financing will support the company's lead preeclampsia program as it moves toward IND-enabling studies.
Timeline
2025: Mitchell Lab VEGF mRNA preeclampsia study published in Nature.
2026: Emvena founded and the PxB Fund formed.
November 4, 2026: PxB Fund announced its first investment in Emvena.
The Tech Race
Emvena applies the mRNA lipid nanoparticle delivery approach that became widely known through COVID-19 vaccines to a new target: the placenta. The shift from vaccines to placenta-directed therapies extends that platform into a condition with no approved disease-modifying treatment.
Preeclampsia is a serious pregnancy complication, and no approved therapy currently treats its underlying disease. Any eventual therapy would depend on the lead program advancing through IND-enabling studies and then clinical trials, a process whose timeline has not been disclosed.
The takeaway
Advances in mRNA delivery are expanding beyond vaccines into targeted treatments for pregnancy-related conditions. Readers tracking biotech funding can watch whether early-stage academic spinouts like Emvena reach clinical testing.
Further reading
For more on the sector, see Biotech coverage of Philadelphia research startups.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Should the government put more funding into medical research on neglected conditions?
